Transitional Cell Carcinoma of the Ureter: Prognostic Factors Influencing Progression and Survival
|
|
- Richard Shepherd
- 6 years ago
- Views:
Transcription
1 european urology 51 (2007) available at journal homepage: Urothelial Cancer Transitional Cell Carcinoma of the Ureter: Prognostic Factors Influencing Progression and Survival Jan Lehmann 1, Henrik Suttmann 1, *, Iva Kovač, Markus Hack, Jörn Kamradt, Stefan Siemer, Bernd Wullich, Ulrike Zwergel, Michael Stöckle Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany Article info Article history: Accepted November 9, 2006 Published online ahead of print on November 17, 2006 Keywords: Transitional cell carcinoma Ureter Upper urinary tract tumour Urothelial cancer Prognostic factors Abstract Objectives: We retrospectively evaluated prognostic factors for progression-free and disease-specific survival in a large cohort of patients with transitional cell carcinoma (TCC) of the ureter. Methods: A single-centre series of 145 consecutive patients treated with partial resection of the ureter or nephroureterectomy between 1975 and 2004 was evaluated. Median follow-up was 96 mo. Routine preoperative laboratory parameters as well as clinical and tumour-specific data were assessed. Univariate and multivariate statistical analyses were performed. Results: Five-year disease-specific survival ranged from 96.1% for stages pta to 28.6% for pt4. Grade1 tumours were associated with 5-yr diseasespecific survival rates of 100% compared with 84% for G2, and 51.9% for G3 tumours, respectively. Univariate analyses identified pt stage and grade, tumour diameter, cm and pn categories, weight loss, the presence of synchronous tumour in the renal pelvis as well as elevated levels for humoral factors such as serum alkaline phosphatase (AP), white blood cell (WBC) count, platelet count, g-glutamyl transferase, creatinin, and blood urea nitrogen as prognostic factors. In multivariate analyses, tumour grade and WBC counts were predictive for low progression-free survival rates, whilst simultaneous tumour in the renal pelvis, high AP levels, and WBC counts were correlated with worse disease-specific survival. Conclusions: Our retrospective analysis provides clinical factors to identify patients with TCC of the ureter at high risk for progression and death of disease. Interestingly, humoral factors such as elevated serum AP levels and high WBC counts were demonstrated to be of paramount prognostic significance besides tumour stage, grade and multifocality. # 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. Department of Urology and Pediatric Urology, Saarland University, Kirrbergerstraße, Homburg/Saar, Germany. Tel. +49 (0) ; Fax: +49 (0) address: henrik.suttmann@uniklinikum-saarland.de (H. Suttmann). 1 J. Lehmann and H. Suttmann contributed equally to this manuscript /$ see back matter # 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eururo
2 1282 european urology 51 (2007) Introduction 2. Patients and methods Upper urinary tract transitional cell carcinoma (UUT-TCC) is a rare disease, accounting for about 5% of all urothelial tumours [1,2]. The incidence accounts for more than 2500 new cases in the United States in 2005, with a male to female ratio of approximately 2:1 [3]. Amongst the known risk factors for the development of UUT-TCC are cigarette smoking, abuse of analgetics, occupational factors, chronic infection and stone disease, as well as antineoplastic agents such as cyclophosphamide [4]. UUT-TCC is often a multifocal disease. Whilst the incidence of bilateral tumours ranges between 2% to 8%, the ipsilateral upper urinary tract is affected in 27 36% by multifocal disease [1,4]. Only2 4%ofUUT-TCCsoccurafter the primary diagnosis of TCC of the urinary bladder [4,5]. In contrast, secondary TCC of the bladder after treatment of UUT-TCC occurs in up to 75% of cases [1,4,6]. Of all UUT-TCCs, about 75% are located in the collecting system of the kidney, whilst 25% occur in the ureter [1,7]. Seventy-three percent of ureteral malignancies involve the distal ureter, whilst 24% and 3% are primarily located in the middle and proximal ureter, respectively [2]. Because of the low incidence of the disease, most studies analyzing prognostic factors have included tumours of the ureter and the renal pelvis. Radical nephroureterectomy with a bladder cuff remains the standard treatment for UUT-TCC [4,7]. Survival at 5 yr following nephroureterectomy depends primarily on tumour grade and stage, and varies from 95% and 90%, respectively, for Ta/T1 tumours to 85% for T2/T3 tumours and 38% for T4 tumours [4,6]. Further prognostic factors with negative impact on survival are multiple tumours, renal insufficiency, and synchronous bladder tumours [8]. Additionally, tumour location has been demonstrated to be of prognostic importance in UUT-TCC with tumours of the renal pelvis having a better prognosis than ureteral tumours [9]. Tumours of the ureter seem to have a higher incidence of local recurrences and distant metastases compared with tumours of the renal pelvis [9]. Only a few studies have investigated prognostic factors in TCC of the ureter separately. We retrospectively evaluated a large cohort of 145 consecutive patients treated for TCC of the ureter in our institution, and performed univariate and multivariate analyses to identify prognostic factors influencing progression and survival Patients We identified 145 consecutive patients who underwent open surgery for TCC of the ureter in our department between 1975 and Patient charts were assessed for histopathologic data including tumour volume, World Health Organization grading and TNM classification [10]. Parameters such as blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum calcium, creatinin, lactate dehydrogenase (LDH), blood urea nitrogen, alanine aminotransferase (ALT), aspartate aminotransferase (AST), g-glutamyl transferase (ggt), bilirubin, alkaline phosphatase (AP), blood sugar, serum protein, and routine coagulation were assessed from patient charts. Furthermore, demographic and clinical data were evaluated, including preoperative body weight, size, and temperature, tumour-related symptoms such as haematuria, weight loss and/or pain, and blood pressure. Routine follow-up consisted of physical examination, ultrasound, cystoscopy, and urine cytology four times per year for the first 2 yr, twice for the third and fourth years, and once yearly thereafter. Additional studies such as intravenous urograms, computed or magnetic resonance tomography, bone scintigraphy, chest x-ray, and/or ureteroscopy were scheduled according to individual patients risk profiles at the discretion of the responsible physician Statistical analyses Progression-free survival and disease-specific survival from time of surgery were defined as end points for this retrospective analysis. Distribution of event times was calculated separately for each of the prognostic factors with the univariate product-limit method by Kaplan-Meier. Continuous variables including tumour size, ESR, blood count, CRP, serum calcium, creatinin, LDH, blood urea nitrogen, ALT, AST, ggt, bilirubin, AP, blood sugar, serum protein, and routine coagulation parameters were dichotomized for this purpose according to the best cutoff value obtained from corresponding, single-factor receiver operator characteristic (ROC) curves with respect to the end points as reported previously [11]. If categoric factors were to be analyzed, all categories were introduced simultaneously into the statistical analysis, except when one category either did not contain or comprised only censored observations. Case censoring was applied in the analysis of progression-free analysis and disease-specific survival when the patient had no signs of recurrence or when death occurred unrelated to tumour during the observation period, respectively. The prognostic significance of each variable was tested univariately with the log-rank test. The simultaneous effects of multiple prognostic factors were estimated by multiple regression analysis by using the Cox proportional hazards model in a forward-selection strategy. Only factors that had a prognostic impact at a significance level ( p) of 0.05 according to the univariate analyses were entered into the multiple regression model. The proportional hazard assumption of these factors was met. Categoric values such as T classification
3 european urology 51 (2007) and tumour grade were assigned as score values, whereas continuous variables entered the model as actual values. All reported p values were based on two-sided tests, and the threshold for significance was Statistical analyses were performed with the Statistical Package for the Social Sciences, version 10.0 (SPSS Inc, Chicago, IL, USA). 3. Results 3.1. Patients and follow-up For the 145 patients with TCC of the ureter, median age was 68 yr with a range of yr. The median follow-up was 96 mo. Table 1 provides further details on patient characteristics. In addition to surgical treatment, 12 patients (8%) received some form of adjuvant systemic chemotherapy. Median overall survival was 70 mo. Seventy-six of 145 patients were dead at the time of analysis. Thirtyone of 145 patients (21%) had died because of tumour progression. Disease-specific survival at 10 yr was 87% for patients with superficial pta/t1 tumours and 36% for patients with muscle-invasive pt2 tumours. For patients undergoing partial ureterectomy, 10-yr progression-free survival was 80%. Of patients undergoing partial ureterectomy, about 10% (5 of 51) experienced an ipsilateral tumour recurrence during the later course Univariate analysis Patient characteristics, and histopathologic and preoperative humoral parameters were subjected to univariate analysis in relation to disease-specific and progression-free survival. Amongst the parameters tested (see Patients and methods), a statistically significant progression-free survival benefit was found for the following (Table 2): tumour diameter (<3.1 cm), serum creatinin (<1.005 mg/dl), alkaline phosphatase (<116 U/l; normal values: <180 U/l for males and <160 U/l for females), total WBC count (< /l); blood urea nitrogen (<39 mg/dl), and platelet count (< /l). Lower pt stages and grades differed favourably between pta versus all other pt stages, except pt1; pt1 versus pt2 and pt1 versus pt3; G2 versus G3 and G1 versus G3. Compared with progression-free survival, the following parameters predicted a statistically significant better outcome for disease-specific survival (Table 3): serum creatinin, tumour diameter, total WBC count, and platelet count (same cutoff as above). Additionally, better survival was correlated with low AP (<127 U/l), ggt (<15.5 U/l), and the absence of positive lymph nodes, distant metastases, weight loss, and a synchronous tumour Table 1 Patient characteristics No. of pts % pts Total Men Women Associated TCC of renal pelvis Side affected Left Right Unknown 7 5 Grade Not classified 12 8 pt category Partial ureterectomy Ta T T2 9 6 T3 3 2 T4 5 3 Not classified 2 1 Nephroureterectomy Ta T T T T4 2 1 Not classified 3 2 PN category pn pn+ 9 6 cm category cm cm Symptomatic disease Yes No Type of surgery Nephroureterectomy Partial resection of ureter Endoscopic laser coagulation 1 1 Simultaneous cystectomy 2 1 Recurrences Ipsilateral after partial ureterectomy 5/51 10 Contralateral 8/145 6 Associated bladder cancer None Before After Before and after 7 5 Pt = patient; TCC = transitional cell carcinoma. of the renal pelvis. Again, various pt stages and grades were highly predictive for a positive outcome: pta versus all other pt stages except pt1; pt1 versus pt3 and pt1 versus pt4; all other pt stages versus pt4; G1 versus G2 and G1 versus G3, as well as
4 1284 european urology 51 (2007) Table 2 Prognostic factors for progression-free survival (univariate analysis) Parameter/cutoff 5-yr progression-free survival (%) SE Median survival (mo) HR 95%CI p value pt category PTa (vs. pt2) n.r pt n.r. pt2 (vs. pt1) pt3 (vs. pt1) pt Grade G1 100 n.r. G2 (vs. G3) n.r G3 (vs. G1) >100 >100 <0.001 Tumor Ø <3.1 cm n.r. >3.1 cm Creatinin <1.005 mg/dl n.r. >1.005 mg/dl n.r AP <116 U/l n.r. >116 U/l n.r WBC count < /l n.r. > /l Blood urea nitrogen <39 mg/dl n.r. >39 mg/dl Platelet count < /l n.r. > /l n.r SE = standard error; HR = hazard ratio; CI = confidence interval; n.r. = not yet reached; AP = alkaline phosphatase; WBC = white blood cell. G2 versus G3 (see Fig. 1A and B for Kaplan-Meier analyses of disease-specific survival according to pt stage and grade). Interestingly, there was no statistically significant benefit for patients undergoing partial resection of the ureter versus those receiving nephroureterectomy (hazard ratio (HR): 0.532; 95% confidence interval [95%CI], ; p = 0.271) Multivariate analysis All significant univariate factors were entered in a stepwise, forward-selection, multivariate Cox regression analysis (Table 4). Low histologic grading was identified as an independent prognostic factor for better progression-free survival. The presence of synchronous tumour in the renal pelvis at the time of surgery and high serum AP were independent negative prognostic factors for disease-specific survival. The only independent prognostic parameter for both progression-free and disease-specific survival was total WBC count (Fig. 1C andd). 4. Discussion TCC of the ureter accounts for only about 25% of all UUT-TCCs [1,7]. Because of this low incidence, most studies investigating prognostic factors in UUT-TCCs have analyzed tumours of the renal pelvis and ureter together. However, according to a recent publication by Park et al [9], TCC of the ureter seems to be associated with a worse prognosis compared with tumours of the renal pelvis. The few studies investigating prognostic factors of the ureter separately are old and hampered by the small number of cases reported per study, ranging between 43 and 73 [2,12 14]. In this retrospective study, we present the largest monocentre patient cohort published to date, in which we investigated prognostic factors in 145 consecutive cases of TCC of the ureter. Additionally, we provide the first analysis of the prognostic significance of various humoral factors in TCC of the ureter. With regards to progression and survival, our results compare favourably with the series of 73
5 european urology 51 (2007) Table 3 Prognostic factors for tumor-specific survival (univariate analysis) Parameter/cutoff 5-yr progression-free survival (%) SE Median survival (mo) HR 95%CI p value pt category pta (vs. pt2) n.r pt1 (vs. pt3) n.r pt2 (vs. pt4) pt pt4 (vs. pt3) Grade G1 (vs. G3) 100 n.r. <0.001 <0.001 <0.001 G2 (vs. G1) n.r. >1000 > G3 (vs. G2) Tumor Ø <3.1 cm n.r. >3.1 cm cm category cm n.r. cm <0.001 pn category pn n.r. pn <0.001 Weight loss No n.r. Yes n.r Creatinin <1.005 mg/dl n.r. >1.005 mg/dl AP <127 U/l n.r. >127 U/l WBC count < /l n.r. > /l <0.001 Platelet count < /l n.r. > /l GGT <15.5 U/l n.r. >15.5 U/l n.r SE = standard error; HR = hazard ratio; CI = confidence interval; n.r. = not yet reached; AP = alkaline phosphatase; WBC = white blood cell; ggt = g-glutamyl transferase. patients with TCC of the ureter published by Zungri et al [14]. In their study, 5-yr overall survival ranged between 100% for pta and 50% for pt2 3 tumours. In our study, 5-yr disease-specific survival ranged from 96.1% for stages pta to 28.6% for pt4. pt stage and grade were significantly correlated with both progression-free and disease-specific survival. Grade1 tumours were associated with a 5-yr diseasespecific survival rate of 100% compared with 84.0% and 51.9% for G2 and G3 tumours, respectively. None of the previous studies on TCC of the ureter analyzed enough patients to perform systematic univariate or multivariate analyses of prognostic factors [2,12 14]. However, they also found a trend towards better outcome for low pt stages and grades. In UUT-TCC including tumours of the ureter and renal pelvis, pt stage and tumour multifocality have recently been identified as prognostic indicators [4]. In addition to tumour stage and grade, we defined several prognostic factors influencing progression and/or survival such as tumour diameter, tumour positive lymph nodes, distant metastases, and the presence of a synchronous tumour in the renal pelvis. Weight loss was the only symptom associated with a negative outcome. A history of previous bladder cancer did not represent an unfavourable prognostic factor as found by others [5]. Furthermore, we identified several
6 1286 european urology 51 (2007) Fig. 1 Kaplan-Meier analyses for disease-specific survival in relation to (A) pt stage, (B) grade, (C) serum alkaline phosphatase (AP), and (D) white blood cell (WBC). HR = hazard ratio; CI = confidence interval. humoral factors that affect the prognosis of patients with TCC of the ureter. The importance of humoral factors for predicting the outcome in patients with solid tumours was acknowledged in 1995 by the College of American Pathologists [15]. Interestingly, in a recent report we were able to demonstrate that certain humoral factors are of superior prognostic value compared with molecular proliferation markers such as Ki-67 status in patients with renal cell carcinoma [11]. Thresholds for serum creatinin (>1.005 mg/dl), AP (>116 U/l), blood urea nitrogen (>39 mg/dl), WBC count (> /l), platelet count (> /l), and ggt (>15.5 U/l) dichotomized our patients with TCC of the ureter into a high-risk and a low-risk cohort. Even though these thresholds were within the normal range of our local laboratory values, they defined subgroups of patients with significantly lower progression-free and/or diseasespecific survival. Elevated levels of serum AP and high WBC counts were even found to be of prognostic impact in multivariate analyses. High AP levels have been shown to be of prognostic significance in other urologic malignancies such as renal cell or prostate cancer as well [11,16,17]. In prostate cancer patients, an elevated AP points to an accelerated bone metabolism and usually indicates the presence of skeletal metastases [17]. In contrast, in renal cell cancer patients an elevated AP often represents the early presence of a paraneoplastic liver dysfunction without necessarily elevating other liver enzymes also in the absence of bone metastases [16]. In our study, none of the patients had radiologically detectable bone metastases at the time of tumour diagnosis. Therefore, higher AP levels are very unlikely to result from occult bone lesions. Our results identify WBC counts > /l as an outstanding factor for predicting progressionfree and disease-specific survival in patients with TCC of the ureter. WBCs in the peripheral blood consist of about 70% neutrophil granulocytes and
7 european urology 51 (2007) Table 4 Prognostic factors for progression-free and tumor-specific survival (multivariate analysis) Parameter/cutoff Regression coefficient SE HR 95%CI of HR p value Progression-free survival Grade WBC count (< /l) <0.001 < Disease-specific survival Synchronous tumor in renal pelvis AP (<127 U/l) WBC (< /l) < SE = standard error; HR = hazard ratio; CI = confidence interval; AP = alkaline phosphatase; WBC = white blood cell. about 20% lymphocytes. Higher WBC counts usually result from a rapid release of immature neutrophils from the bone marrow as a sign of high cell turnover at distant inflammatory sites. In recent years, a newly discovered putative role of neutrophil granulocytes in malignant tumour growth and tumour immunology has been a matter of intensive debate. Whilst most studies suggest a tumour-promoting nursing function of neutrophils in advanced disease, under certain circumstances they also seem to exert tumour-inhibitory actions during early cancer cell growth [18,19]. The identification of higher WBC counts as an independent prognostic factor in TCC of the ureter might reflect an early futile activation of the innate immune system in response to local and/or metastatic tumour spread. Recent data on adjuvant systemic chemotherapy for locally advanced upper urinary tract cancer has been contradictory: Adjuvant chemotherapy for pt3n0m0 TCC has not proven useful in terms of improving survival [20]; however, another group from Korea has reported a significant survival benefit in 16 of 27 patients receiving cisplatinumbased chemotherapy [21]. Data on combined adjuvant radiochemotherapy has been even more limited. Nevertheless a group from Boston [22] presented data on 31 patients, concluding that the addition of concurrent cisplatin to adjuvant radiotherapy improves the ultimate outcome in patients with resected, locally advanced upper tract urothelial malignancies. They recommend that such a regimen be considered in patients with T3 4 and/or node-positive upper tract TCC. In our patient cohort, more than one third of patients received a partial resection of the affected ureteral segment with nephroureterectomy, representing the more prevalent surgical procedure. In fact, when comparing patients with pta or pt1 (cn0, cm0) ureteral tumours, no difference in survival was found for partial ureterectomy or nephroureterectomy (data not shown). Therefore, from our experience, conservative surgery is a valid option mainly in Ta/T1 lesions, which could be established from the beginning of our observation period. Whilst we did not detect a statistically significant difference for partial ureteral resection versus nephroureterectomy, we cannot provide insights from our experience on the ongoing debate about the prognostic impact of a conservative (endoscopic) versus an open surgical approach for TCC of the ureter. However, the data available to date suggest that intraluminal surgical techniques should only be applied in low-grade and low-stage tumours [4]. 5. Conclusions We provide data on prognostic factors in TCC of the ureter from the largest monocentre patient cohort published to date. Tumour stage and grade, tumour diameter, metastatic and symptom status, and multifocality as well as various humoral factors such as elevated serum AP levels or WBC counts were demonstrated to predict clinical responses. Our results will help to identify patients with ureteral tumours at high risk for progression and might provide a tool to stratify patients into different risk groups for yet-to-be-established adjunctive treatment such as systemic chemotherapy. References [1] Hall MC, Womack S, Sagalowsky AI, et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52: [2] Babaian RJ, Johnson DE. Primary carcinoma of the ureter. J Urol 1980;123: [3] Jemal A, Murray T, Ward E, et al. Cancer statistics, CA Cancer J Clin 2005;55: [4] Oosterlinck W, Solsona E, van der Meijden AP, et al. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol 2004;46:
8 1288 european urology 51 (2007) [5] Hurle R, Losa A, Manzetti A, et al. Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients. Urology 1999;53: [6] Kakizoe T, Fujita J, Murase T, et al. Transitional cell carcinoma of the bladder in patients with renal pelvic and ureteral cancer. J Urol 1980;124:17 9. [7] Krogh J, Kvist E, Rye B. Transitional cell carcinoma of the upper urinary tract: prognostic variables and postoperative recurrences. Br J Urol 1991;67:32 6. [8] Kang CH, Yu TJ, Hsieh HH, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003;98: [9] Park S, Hong B, Kim CS, et al. The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol 2004;171: [10] Sobin LH, Fleming ID. TNM classification of malignant tumors. 5th ed. (1997) Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80: [11] Lehmann J, Retz M, Nürnberg N, et al. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 2004;101: [12] Batata MA, Whitmore WF, Hilaris BS, et al. Primary carcinoma of the ureter: a prognostic study. Cancer 1975;35: [13] Anderstrom C, Johansson SL, Pettersson S, et al. Carcinoma of the ureter: a clinicopathologic study of 49 cases. J Urol 1989;142: [14] Zungri E, Chechile G, Algaba F, et al. Treatment of transitional cell carcinoma of the ureter: is the controversy justified? Eur Urol 1990;17: [15] Henson DE, Fielding LP, Grignon DJ, et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors Summary. Members of the Cancer Committee. Arch Pathol Lab Med 1995;119: [16] Stauffer M. Nephrogenic hepatoslenomegaly. Gastroenterology 1961;40: [17] Jorgensen T, Kanagasingam Y, Kaalhus O, et al. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2. J Urol 1997;158: [18] Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: [19] Di Carlo E, Forni G, Musiani P. Neutrophils in the antitumoral immune response. In: Cassatella MA, editor. The neutrophil. Basel: Karger; p [20] Lee SE, Byun SS, Park YH, et al. Adjuvant chemotherapy in the management of pt3n0m0 transitional cell carcinoma of the upper urinary tract. Urol Int 2006;77:22 6. [21] Kwak C, Lee SE, Jeong IG, et al. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 2006;68:53 7. [22] Czito B, Zietman A, Kaufman D, et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol 2004;172:
Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy
Brazilian Journal of Medical and Biological Research (2007) 40: 979-984 Predictive factors after radical cystectomy ISSN 0100-879X 979 Multiple factor analysis of metachronous upper urinary tract transitional
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationTransitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as a Spinal Cord Compression
Case Study TheScientificWorldJOURNAL (2008) 8, 223 227 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2008.43 Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as
More informationThe Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma
Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationGUIDELINES ON RENAL CELL CANCER
20 G. Mickisch (chairman), J. Carballido, S. Hellsten, H. Schulze, H. Mensink Eur Urol 2001;40(3):252-255 Introduction is characterised by a constant rise in incidence over the last 50 years, with a predominance
More informationSegmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer
Int Urol Nephrol (2014) 46:921 926 DOI 10.1007/s11255-013-0514-z UROLOGY - ORIGINAL PAPER Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationClinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationENDOSCOPIC URETERECTOMY DURING NEPHROURETERECTOMY FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA
ENDOSCOPIC URETERECTOMY DURING NEPHROURETERECTOMY FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA Il. Saltirov, Ts. Petkov, G. Georgiev, K.Petkova Department of Urology and Nephrology, Military Medical
More informationUpper Tract Tcc. Mohan Arianayagam FRACS (Urology)
Upper Tract Tcc Mohan Arianayagam FRACS (Urology) Epidemiology Peak incidence 75 to 79 years 2x more common in men 7% of all renal tumours 5% of all urothelial tumours Synchronous bilateral is rare ~ 1.6%
More informationUrothelial carcinomas of the upper urinary tract how does UK practice compare with European guidelines: is there a difference?
699543URO0010.1177/2051415817699543Journal of Clinical UrologyMoon et al. research-article2018 EAU Guidelines Urothelial carcinomas of the upper urinary tract how does UK practice compare with European
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationAttachment #2 Overview of Follow-up
Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationThe Characteristics of Recurrent Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy without Bladder Cuff Excision
Original Article http://dx.doi.org/10.3349/ymj.2015.56.2.375 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 56(2):375-381, 2015 The Characteristics of Recurrent Upper Tract Urothelial Carcinoma after
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationRadical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors
ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau
More informationAttachment #2 Overview of Follow-up
Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer
More informationShould the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer
Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology
More informationCitation International journal of urology (2. Right which has been published in final f
Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib
More informationIs There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented by the Revised 7th TNM Version?
EUROPEAN UROLOGY 59 (2011) 258 263 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Is There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented
More informationRole and extension of lymph node dissection in kidney, bladder and prostate cancer. Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017
Role and extension of lymph node dissection in kidney, bladder and prostate cancer Omar Ghanem (PGY3 ) Moderator: Dr A. Noujem 30 th March 2017 Bladder Cancer LN dissection in Bladder cancer 25% of patients
More informationClinical Value of C-reactive Protein and Erythrocyte Sedimentation Rate in Advanced Bladder Cancer
Original Article Research in Oncology 2018; Vol. XX, No. X: X-X. DOI: 10.21608/resoncol.2018.4152.1060 Clinical Value of C-reactive Protein and Erythrocyte Sedimentation Rate in Advanced Bladder Cancer
More informationPrognostic Impact of Peripelvic Fat Invasion in pt3 Renal Pelvic Transitional Cell Carcinoma
J Korean Med Sci 2008; 23: 434-8 ISSN 1011-8934 DOI: 10.3346/jkms.2008.23.3.434 Copyright The Korean Academy of Medical Sciences Prognostic Impact of Peripelvic Fat Invasion in pt3 Renal Pelvic Transitional
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationOutcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing Radical Prostatectomy
european urology 52 (2007) 1058 1066 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Outcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationGlossary of Terms Primary Urethral Cancer
Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationUrological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor
More informationUpper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma
DOI 10.1007/s00345-012-0877-2 ORIGINAL ARTICLE Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma Marco Cosentino Joan Palou Josep M. Gaya
More informationLong-Term Oncologic Outcome after Laparoscopic Radical Nephroureterectomy for Upper Tract Transitional Cell Carcinoma
european urology 51 (2007) 1639 1644 available at www.sciencedirect.com journal homepage: www.europeanurology.com Laparoscopy Long-Term Oncologic Outcome after Laparoscopic Radical Nephroureterectomy for
More informationABSTRACT. Shuisheng Zhang 1, Xiaozhun Huang 2, Yuan Tian 3, Saderbieke Aimaiti 1, Jianwei Zhang 1, Jiuda Zhao 4, Yingtai Chen 1 and Chengfeng Wang 1
Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients in China Shuisheng Zhang 1, Xiaozhun Huang
More informationUreteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes
ORIGINAL ARTICLE Vol. 43 (x): 2017 August 8.[Ahead of print] doi: 10.1590/S1677-5538.IBJU.2017.0218 Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes Muammer
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationBladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist
Bladder Cancer in Primary Care Dr Penny Kehagioglou Consultant Clinical Oncologist Objectives Patient presentation in primary care Investigating bladder cancer Management of bladder cancer Differential
More informationClinical Study Ureteroscopic Laser Treatment of Upper Urinary Tract Urothelial Cell Carcinomas: Can a Tumour Free Status Be Achieved?
Advances in Urology Volume 2013, Article ID 429585, 4 pages http://dx.doi.org/10.1155/2013/429585 Clinical Study Ureteroscopic Laser Treatment of Upper Urinary Tract Urothelial Cell Carcinomas: Can a Tumour
More informationsymposium article introduction symposium article
Annals of Oncology 17 (Supplement 5): v118 v122, 2006 doi:10.1093/annonc/mdj965 Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/ vinblastine/doxorubicin/cisplatin
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationClinical Trial Results Database Page 1
Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study
More informationHierro-Majadahonda, Universidad Aut ó noma de Madrid, Madrid, Spain,
BJUI BJU INTERNATIONAL Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without
More informationUrological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi
Urological Oncology Predicting Recurrence and Progression in Non-Muscle- Invasive Bladder Cancer Using European Organization of Research and Treatment of Cancer Risk Tables M Hammad Ather, Masooma Zaidi
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationUreteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor
Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor Scott G. Hubosky, MD The Demetrius H. Bagley Jr., MD Associate Professor of Urology Director of Endourology Vice Chair
More informationHydronephrosis as a Prognostic Marker in Bladder Cancer in a Cystectomy-Only Series
european urology 51 (2007) 690 698 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Hydronephrosis as a Prognostic Marker in Bladder Cancer in a Cystectomy-Only
More informationRenal tumors of adults
Renal tumors of adults Urinary Tract Tumors 2%-3% of all cancers in adults. The most common malignant tumor of the kidney is renal cell carcinoma. Tumors of the lower urinary tract are twice as common
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationCase Report Stereotactic Body Radiotherapy for Localized Ureter Transitional Cell Carcinoma: Three Case Reports
Case Reports in Urology Volume 2015, Article ID 519897, 4 pages http://dx.doi.org/10.1155/2015/519897 Case Report Stereotactic Body Radiotherapy for Localized Ureter Transitional Cell Carcinoma: Three
More informationCarcinoma of the Renal Pelvis and Ureter Histopathology
Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More information3.1 Investigations for Patients Presenting with Haematuria Table 1
3.1 Investigations for Patients Presenting with Haematuria Table 1 Patients at risk of bacterial endocarditis should be given antibiotic prophylaxis as per local guidelines. Patients with heart valve replacements
More informationA Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer
More informationPreoperative risk factors for extraurothelial recurrence in N0M0 patients with renal pelvic cancer treated by radical nephroureterectomy
530 Preoperative risk factors for extraurothelial recurrence in N0M0 patients with renal pelvic cancer treated by radical nephroureterectomy KEIICHI ITO, JUNICHI ASAKUMA, KENJI KURODA, KAZUYOSHI TACHI,
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1123 1130 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence
More informationGUIDELINES ON RENAL CELL CARCINOMA
GUIDELINES ON RENAL CELL CARCINOMA B. Ljungberg (chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction This EAU guideline was prepared to help urologists
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationCanadian Urological Association guidelines for followup of patients after treatment of nonmetastatic
Canadian Urological Association guidelines for followup of patients after treatment of nonmetastatic renal cell carcinoma Wassim Kassouf, Leonardo L. Monteiro, Darrel E. Drachenberg, Adrian S. Fairey,
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationResearch Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationElevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma
1142 Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma FARUK TAS and KAYHAN ERTURK Department of Medical Oncology,
More informationDepartment of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. 2
UROLOGICAL ONCOLOGY Effects of Previous or Synchronous Non-Muscle Invasive Bladder Cancer on Clinical Results after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multi-Institutional
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationBladder cancer - suspected
Background information Information resources for patients and carers Updates to this care map Bladder cancer - clinical presentation History Examination Consider differential diagnoses Clinical indications
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationArieh L. Shalhav Is There a Risk in Robotic Nephroureterectomy?
Arieh L. Shalhav Is There a Risk in Robotic Nephroureterectomy? 80 patients LNU (n = 40) or ONU (n = 40) CSS (p = 0.2), BRFS (p = 0.86), MFS (p = 0.12) similar for the entire cohort Subgroups of pt3 UTUC
More information5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.
Bladder Case Scenario 1 History 5/23/16: A 52-year-old male, smoker was admitted to our hospital with a 3-month history of right pelvic pain, multiple episodes of gross hematuria, dysuria, and extreme
More informationComparative Outcomes of Primary, Recurrent, and Progressive High-risk Non muscle-invasive Bladder Cancer
EUROPEAN UROLOGY 63 (2013) 145 154 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Urothelial Cancer Editorial by J. Alfred Witjes on pp. 155 157 of this
More informationUpper Tract Urothelial Carcinomas (UTUCs)
Upper Tract Urothelial Carcinomas (UTUCs) Part II: UTUC Treatment Options November 14, 2017 Moderated by: Presented by: Gary D. Steinberg, MD University of Chicago Medical Center Ahmad Shabsigh, MD Ohio
More informationSymptoms, Diagnosis and Classification
Patient Information English 2 Symptoms, Diagnosis and Classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationChemotherapy Treatment Algorithms for Urology Cancer
Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series
Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationSupplementary Material
1 Supplementary Material 3 Tumour Biol. 4 5 6 VCP Gene Variation Predicts Outcome of Advanced Non-Small-Cell Lung Cancer Platinum-Based Chemotherapy 7 8 9 10 Running head: VCP variation predicts NSCLC
More informationSAMPLING OF POST NEPHRECTOMY CANCER CARE (5)
SAMPLING OF POST NEPHRECTOMY CANCER CARE (5) Universally recognized post-nephrectomy cancer treatment. Sampling: National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidelines in Oncology
More informationThe Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor
Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In
More informationPrognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy
European Urology European Urology 45 (2004) 292 296 Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy Barthold Ph. Schrier a, Maarten
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationPrognostic Impact of Extensive Parenchymal Invasion Pattern in pt3 Renal Pelvic Transitional Cell Carcinoma
3150 Prognostic Impact of Extensive Parenchymal Invasion Pattern in pt3 Renal Pelvic Transitional Cell Carcinoma Koji Yoshimura, M.D. 1 Yoichi Arai, M.D., Ph.D. 1 Hiroyuki Fujimoto, M.D. 2 Hiroyuki Nishiyama,
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More information